Stock EXACT THERAPEUTICS AS
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

EXACT Therapeutics AS Stock Oslo Bors

Equities

NO0010852213

Biotechnology & Medical Research

Financials

Sales 2022 455K 41.23K Sales 2023 4.46K 404.36 Capitalization 385M 34.92M
Net income 2022 -40M -3.63M Net income 2023 -48M -4.35M EV / Sales 2022 643 x
Net cash position 2022 67.7M 6.14M Net cash position 2023 45.23M 4.1M EV / Sales 2023 76,207 x
P/E ratio 2022
-8.96 x
P/E ratio 2023
-7.95 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 34.72%
More Fundamentals * Assessed data

Chart EXACT Therapeutics AS

Dynamic Chart

Latest news about EXACT Therapeutics AS

EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study MT
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2023 CI
EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023 CI
Exact Therapeutics Jumps 13% After Positive Outcomes From Acoustic Cluster Therapy Trial MT
EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose Escalation CI
Exact Therapeutics, Cordance Medical to Collaborate on Drug Delivery Solutions for Brain Treatment MT
EXACT Therapeutics and Cordance Medical Announce Strategic Partnership to Revolutionize Drug Delivery to the Brain CI
Exact Therapeutics Concludes Dose Escalation Under Cancer Therapy Study MT
EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE Study CI
EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE Study CI
EXACT Therapeutics AS Announces Management Changes CI
EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2022 CI
EXACT THERAPEUTICS AS Presents Encouraging Clinical Case Report Data At Science & Technology Event CI
Exact Therapeutics Gets UK Clearance to Reopen Phase 1 Acoustic Cluster Therapy Trial MT
More news

Press releases EXACT Therapeutics AS

EXACT Therapeutics : Successful placement of NOK 25 million share issue PU
Additional promising clinical data from EXACT Therapeutics' ongoing ACTIVATE study presented at AACR Annual Meeting AQ
EXACT Therapeutics to Present at 2024 American Association for Cancer Research (AACR) Annual Meeting AQ
EXACT Therapeutics AS - Share capital increase registered AQ
EXACT Therapeutics presenting at DNB Nordic Healthcare conference December 14 AQ
More press releases

Managers and Directors - EXACT Therapeutics AS

Managers TitleAgeSince
Svein Kvåle FOU
 Founder - 11-12-31
Per Walday CEO
 Chief Executive Officer 64 22-03-27
John Edminson DFI
 Director of Finance/CFO - 22-09-30
Members of the board TitleAgeSince
William Castell BRD
 Director/Board Member 76 18-06-21
Ann-Tove Kongsnes BRD
 Director/Board Member 57 -
Masha Paule Nathalie Strømme BRD
 Director/Board Member 53 14-12-31
More insiders

Company Profile

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.
Sector
Biotechnology & Medical Research
Calendar
2024-06-06 - Annual General Meeting
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.59B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 40.65B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 40.57B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 24.81B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.7B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11.1B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EXTX Stock
  4. Stock